BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 10837621)

  • 1. Man-made superantigens: Tumor-selective agents for T-cell-based therapy.
    Dohlsten M; Kalland T; Gunnarsson P; Antonsson P; Molander A; Olsson J; d'Argy R; Ohlsson L; Soegaard M; Persson R; Brodin TN
    Adv Drug Deliv Rev; 1998 Apr; 31(1-2):131-142. PubMed ID: 10837621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superantigen natural affinity maturation revealed by the crystal structure of staphylococcal enterotoxin G and its binding to T-cell receptor Vbeta8.2.
    Fernández MM; Bhattacharya S; De Marzi MC; Brown PH; Kerzic M; Schuck P; Mariuzza RA; Malchiodi EL
    Proteins; 2007 Jul; 68(1):389-402. PubMed ID: 17427250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conservation and variation in superantigen structure and activity highlighted by the three-dimensional structures of two new superantigens from Streptococcus pyogenes.
    Arcus VL; Proft T; Sigrell JA; Baker HM; Fraser JD; Baker EN
    J Mol Biol; 2000 May; 299(1):157-68. PubMed ID: 10860729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetically engineered superantigens as tolerable antitumor agents.
    Hansson J; Ohlsson L; Persson R; Andersson G; Ilbäck NG; Litton MJ; Kalland T; Dohlsten M
    Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2489-94. PubMed ID: 9122222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Xenogeneic cells and superantigen induce human T-cell activation in the absence of T-cell recognition of xenoantigen.
    Diaz LA; Pai R; Endres J; Anthony P; Duzyj C; Bishu S; Morita Y; Fox DA
    J Lab Clin Med; 2003 Sep; 142(3):149-57. PubMed ID: 14532902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interplay between superantigens and immunoreceptors.
    Petersson K; Forsberg G; Walse B
    Scand J Immunol; 2004 Apr; 59(4):345-55. PubMed ID: 15049778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naptumomab estafenatox, an engineered antibody-superantigen fusion protein with low toxicity and reduced antigenicity.
    Forsberg G; Skartved NJ; Wallén-Ohman M; Nyhlén HC; Behm K; Hedlund G; Nederman T
    J Immunother; 2010 Jun; 33(5):492-9. PubMed ID: 20463598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells.
    Cohen CJ; Hoffmann N; Farago M; Hoogenboom HR; Eisenbach L; Reiter Y
    Cancer Res; 2002 Oct; 62(20):5835-44. PubMed ID: 12384546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit.
    Lev A; Denkberg G; Cohen CJ; Tzukerman M; Skorecki KL; Chames P; Hoogenboom HR; Reiter Y
    Cancer Res; 2002 Jun; 62(11):3184-94. PubMed ID: 12036932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fab antibodies capable of blocking T cells by competitive binding have the identical specificity but a higher affinity to the MHC-peptide-complex than the T cell receptor.
    Neumann F; Sturm C; Hülsmeyer M; Dauth N; Guillaume P; Luescher IF; Pfreundschuh M; Held G
    Immunol Lett; 2009 Aug; 125(2):86-92. PubMed ID: 19524620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune selection in murine tumors. Ph.d thesis.
    Svane IM; Engel AM
    APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining tumor-targeted superantigens with interferon-alpha results in synergistic anti-tumor effects.
    Sundstedt A; Celander M; Hedlund G
    Int Immunopharmacol; 2008 Mar; 8(3):442-52. PubMed ID: 18279798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy.
    Dohlsten M; Abrahmsén L; Björk P; Lando PA; Hedlund G; Forsberg G; Brodin T; Gascoigne NR; Förberg C; Lind P
    Proc Natl Acad Sci U S A; 1994 Sep; 91(19):8945-9. PubMed ID: 8090750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The crystal structure of staphylococcal enterotoxin H: implications for binding properties to MHC class II and TcR molecules.
    Hâkansson M; Petersson K; Nilsson H; Forsberg G; Björk P; Antonsson P; Svensson LA
    J Mol Biol; 2000 Sep; 302(3):527-37. PubMed ID: 10986116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational analysis of the binding of staphylococcal enterotoxin D to the T cell receptor Vbeta chain and major histocompatibility complex class II.
    Li Y; Zhu X; Huang Y; Xiong H
    Immunol Lett; 2006 May; 105(1):55-60. PubMed ID: 16481046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral IL-18 gene transfer improves therapeutic efficacy of antibody-targeted superantigen in established murine melanoma.
    Wang Q; Yu H; Ju DW; He L; Pan JP; Xia DJ; Zhang LH; Cao X
    Gene Ther; 2001 Apr; 8(7):542-50. PubMed ID: 11319621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation and in-vitro bioactivity of a novel superantigen conjugate targeting bladder carcinoma.
    Zhen G; Cong-hui H; Lin H; Jian-jun Y; Wen-hao T; Gao-jun T
    J Pharm Pharmacol; 2009 Jul; 61(7):869-75. PubMed ID: 19589228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction between superantigen and T-cell receptor Vbeta element determines levels of superantigen-dependent cell-mediated cytotoxicity of CD8(+) T cells in induction and effector phases.
    Li ZJ; Omoe K; Shinagawa K; Yagi J; Imanishi K
    Microbiol Immunol; 2009 Aug; 53(8):451-9. PubMed ID: 19659929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crystal structure of the streptococcal superantigen SpeI and functional role of a novel loop domain in T cell activation by group V superantigens.
    Brouillard JN; Günther S; Varma AK; Gryski I; Herfst CA; Rahman AK; Leung DY; Schlievert PM; Madrenas J; Sundberg EJ; McCormick JK
    J Mol Biol; 2007 Apr; 367(4):925-34. PubMed ID: 17303163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [MHC tetramers: tracking specific immunity].
    Kosor E; Gagro A; Drazenović V; Kuzman I; Jeren T; Rakusić S; Rabatić S; Markotić A; Gotovac K; Sabioncello A; Cecuk E; Kerhin-Brkljacić V; Gjenero-Margan I; Kaić B; Mlinarić-Galinović G; Kastelan A; Dekaris D
    Acta Med Croatica; 2003; 57(4):255-9. PubMed ID: 14639858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.